Gujarat Themis Biosyn Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 23, 2024, 9:54 am

Market Cap	3,389 Cr.
Current Price	311
High / Low	390/128
Stock P/E	64.3
Book Value	20.5
Dividend Yield	0.22 %
ROCE	45.0 %
ROE	33.8 %
Face Value	1.00
PEG Ratio	5.11

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Gujarat Themis Biosyn Ltd

Competitors of

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,389 Cr.	311	390/128	64.3	20.5	0.22 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	62.5 Cr.	84.2	94.9/26.6	24.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	37.6 Cr.	25.7	25.7/8.74	48.9	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	87.4 Cr.	116	155/87.0	13.1	55.4	0.00 %	14.4 %	15.5 %	10.0
Glenmark Life Sciences Ltd	12,192 Cr.	995	1,335/645	28.8	207	2.25 %	28.1 %	21.1 %	2.00
Industry Average	18,989.69 Cr	1,176.87		55.72	186.30	0.32%	16.20%	16.32%	6.27

All Competitor Stocks of

Quarterly Result

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	35	19	29	45	48	28	28	50	40	39	42	39	35
Expenses	17	9	16	22	23	16	13	26	23	21	21	20	19
Operating Profit	18	10	13	23	24	12	14	24	17	17	21	19	15
OPM %	53%	53%	45%	51%	51%	43%	52%	47%	42%	45%	50%	48%	44%
Other Income	1	1	2	1	1	2	2	1	1	1	1	1	0
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	1
Profit before tax	18	10	14	24	25	13	16	24	17	18	21	18	14
Tax %	25%	26%	29%	25%	26%	26%	25%	26%	26%	26%	24%	26%	26%
Net Profit	14	7	10	18	19	10	12	18	13	13	16	13	11
EPS in Rs	1.27	0.65	0.90	1.63	1.72	0.90	1.07	1.63	1.15	1.19	1.46	1.21	0.97

Last Updated: November 6, 2024, 6:35 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:18 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	28	30	31	33	36	39	41	85	91	115	148	170	159
Expenses	25	24	25	27	30	33	34	53	50	57	75	91	85
Operating Profit	3	6	7	6	6	6	7	32	40	58	74	79	74
OPM %	11%	21%	21%	19%	17%	16%	18%	37%	45%	51%	50%	46%	46%
Other Income	0	0	-0	0	0	0	2	2	3	4	7	4	4
Interest	1	1	0	0	0	0	0	1	1	1	0	0	0
Depreciation	1	1	1	1	1	1	1	1	2	2	3	4	4
Profit before tax	1	5	5	5	5	5	8	31	41	59	77	79	73
Tax %	0%	0%	0%	0%	10%	20%	22%	24%	26%	26%	25%	25%
Net Profit	1	5	5	5	4	4	6	24	30	44	58	59	55
EPS in Rs	0.10	0.42	0.42	0.42	0.40	0.36	0.59	2.17	2.77	4.00	5.32	5.43	5.01
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	10%	0%	37%	14%	12%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	400.00%	0.00%	0.00%	-20.00%	0.00%	50.00%	300.00%	25.00%	46.67%	31.82%	1.72%
Change in YoY Net Profit Growth (%)	0.00%	-400.00%	0.00%	-20.00%	20.00%	50.00%	250.00%	-275.00%	21.67%	-14.85%	-30.09%

Gujarat Themis Biosyn Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	19%
5 Years:	33%
3 Years:	23%
TTM:	6%

Compounded Profit Growth
10 Years:	29%
5 Years:	56%
3 Years:	25%
TTM:	2%

Stock Price CAGR
10 Years:	59%
5 Years:	114%
3 Years:	70%
1 Year:	136%

Return on Equity
10 Years:	%
5 Years:	45%
3 Years:	41%
Last Year:	34%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 1:33 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	7	7	7	7	7	7	7	7	7	7	7	7	11
Reserves	-17	-13	-8	-3	1	5	11	35	63	96	142	194	213
Borrowings	11	9	6	3	4	1	6	8	5	1	0	3	3
Other Liabilities	17	13	9	8	9	8	8	14	14	18	17	17	21
Total Liabilities	18	16	15	15	21	20	33	64	88	122	166	221	248
Fixed Assets	12	11	10	9	11	11	15	17	19	19	33	38	42
CWIP	-0	0	0	0	0	0	1	0	2	13	21	91	136
Investments	0	0	0	0	0	0	0	0	-0	-0	-0	-0	-0
Other Assets	6	5	5	5	11	10	17	47	67	90	113	92	69
Total Assets	18	16	15	15	21	20	33	64	88	122	166	221	248

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	0	4	3	4	3	6	1	1	11	40	39	64
Cash from Investing Activity +	-3	-0	-0	-1	-3	-1	-6	-3	-2	-30	-20	-55
Cash from Financing Activity +	2	-3	-3	-3	-0	-4	5	2	-5	-14	-13	-9
Net Cash Flow	-0	1	-1	-0	0	1	0	-0	3	-4	6	0

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-8.00	-3.00	1.00	3.00	2.00	5.00	1.00	24.00	35.00	57.00	74.00	76.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	37	15	28	24	71	26	52	87	59	80	44	58
Inventory Days	58					78		194	144	255	201	33
Days Payable	1,498					947		240	84	145	131	99
Cash Conversion Cycle	-1,403	15	28	24	71	-844	52	41	119	189	114	-7
Working Capital Days	-172	-128	-76	-69	-30	-43	-58	42	96	158	92	53
ROCE %		208%	121%	81%	55%	42%	45%	84%	67%	67%	61%	45%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	74.99%	74.99%	74.99%	75.00%	75.00%	75.00%	75.00%	75.00%	70.87%	70.87%	70.87%	70.87%
FIIs	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.01%	0.01%	0.86%	1.05%	1.44%	1.49%
DIIs	0.31%	0.31%	0.31%	0.03%	0.03%	0.03%	0.03%	0.03%	0.04%	0.82%	1.18%	1.17%
Public	24.70%	24.70%	24.69%	24.98%	24.96%	24.95%	24.95%	24.96%	28.23%	27.26%	26.52%	26.47%
No. of Shareholders	13,059	13,917	13,830	14,904	16,550	16,804	17,373	19,846	28,655	29,576	30,280	31,271

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal BSE Healthcare ETF	438	0.09	0.02	438	2024-12-17	0%

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	8.14	39.90	30.03	20.77	16.30
Diluted EPS (Rs.)	8.14	39.90	30.03	20.77	16.30
Cash EPS (Rs.)	8.63	41.67	31.56	21.96	17.23
Book Value[Excl.RevalReserv]/Share (Rs.)	27.72	102.66	71.11	48.14	29.04
Book Value[Incl.RevalReserv]/Share (Rs.)	27.72	102.66	71.11	48.14	29.04
Dividend / Share (Rs.)	1.00	5.40	11.00	1.65	1.65
Revenue From Operations / Share (Rs.)	23.38	102.54	79.05	62.33	58.59
PBDIT / Share (Rs.)	11.44	55.23	42.74	29.42	23.09
PBIT / Share (Rs.)	10.95	53.46	41.20	28.23	22.15
PBT / Share (Rs.)	10.92	53.32	40.63	28.14	21.51
Net Profit / Share (Rs.)	8.14	39.90	30.03	20.77	16.30
PBDIT Margin (%)	48.93	53.86	54.06	47.19	39.40
PBIT Margin (%)	46.85	52.13	52.12	45.28	37.80
PBT Margin (%)	46.71	51.99	51.39	45.14	36.71
Net Profit Margin (%)	34.83	38.91	37.98	33.32	27.81
Return on Networth / Equity (%)	29.37	38.86	42.22	43.14	56.10
Return on Capital Employeed (%)	38.82	51.41	56.82	56.61	68.85
Return On Assets (%)	26.75	34.85	35.61	34.19	36.94
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.07
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.07
Asset Turnover Ratio (%)	0.87	1.03	1.09	1.19	1.76
Current Ratio (X)	2.94	3.98	4.57	4.00	1.65
Quick Ratio (X)	2.74	3.03	3.89	3.62	1.31
Inventory Turnover Ratio (X)	2.86	2.27	2.46	2.61	4.85
Dividend Payout Ratio (NP) (%)	11.66	21.05	23.31	7.94	0.00
Dividend Payout Ratio (CP) (%)	11.00	20.15	22.17	7.51	0.00
Earning Retention Ratio (%)	88.34	78.95	76.69	92.06	0.00
Cash Earning Retention Ratio (%)	89.00	79.85	77.83	92.49	0.00
Interest Coverage Ratio (X)	362.56	399.81	75.01	329.82	36.33
Interest Coverage Ratio (Post Tax) (X)	259.13	289.83	53.70	233.87	26.64
Enterprise Value (Cr.)	2869.27	987.92	579.63	268.24	142.31
EV / Net Operating Revenue (X)	16.90	6.63	5.05	2.96	1.67
EV / EBITDA (X)	34.53	12.31	9.33	6.28	4.24
MarketCap / Net Operating Revenue (X)	16.94	6.69	5.15	3.27	1.66
Retention Ratios (%)	88.33	78.94	76.68	92.05	0.00
Price / BV (X)	14.29	6.69	5.73	4.23	3.35
Price / Net Operating Revenue (X)	16.94	6.69	5.15	3.27	1.66
EarningsYield	0.02	0.05	0.07	0.10	0.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gujarat Themis Biosyn Ltd as of December 23, 2024 is: 446.51

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 23, 2024, Gujarat Themis Biosyn Ltd is Undervalued by 43.57% compared to the current share price 311.00

Intrinsic Value of Gujarat Themis Biosyn Ltd as of December 23, 2024 is: 502.69

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 23, 2024, Gujarat Themis Biosyn Ltd is Undervalued by 61.64% compared to the current share price 311.00

Last 5 Year EPS CAGR: 12.58%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 73.00%, which is a positive sign. The stock has a low average Working Capital Days of -11.25, which is a positive sign. The stock has a low average Cash Conversion Cycle of -16.58, which is a positive sign. The company has higher reserves (55.31 cr) compared to borrowings (4.62 cr), indicating strong financial stability. The company has shown consistent growth in sales (77.38 cr) and profit (30.31 cr) over the years.

Strength

Weakness

The stock has a high average ROCE of 73.00%, which is a positive sign.
The stock has a low average Working Capital Days of -11.25, which is a positive sign.
The stock has a low average Cash Conversion Cycle of -16.58, which is a positive sign.
The company has higher reserves (55.31 cr) compared to borrowings (4.62 cr), indicating strong financial stability.
The company has shown consistent growth in sales (77.38 cr) and profit (30.31 cr) over the years.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Themis Biosyn Ltd:
1. Net Profit Margin: 34.83%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 38.82% (Industry Average ROCE: 16.2%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 29.37% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 259.13
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.74
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 64.3 (Industry average Stock P/E: 55.72)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Gujarat Themis Biosyn Ltd. is a Public Limited Listed company incorporated on 11/12/1981 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1981PLC004878 and registration number is 004878. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 114.85 Cr. and Equity Capital is Rs. 7.26 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Plot NO. 69-C, G.I.D.C., Valsad District Gujarat 396195	gtblmumbai@gtbl.in http://www.gtbl.in

Management
Name	Position Held
Dr. Dinesh S Patel	Chairman & Non-Exe.Director
Dr. Sachin D Patel	Promoter Non-Exe.Director
Mr. Vijay Agarwal	Ind. Non-Executive Director
Dr. Vikram D Sanghvi	Ind. Non-Executive Director
Mr. Siddharth Y Kusumgar	Ind. Non-Executive Director
Mrs. Kirandeep Kaur Madan	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of Gujarat Themis Biosyn Ltd?

The latest intrinsic value of Gujarat Themis Biosyn Ltd as on 23 December 2024 is ₹446.51, which is 43.57% higher than the current market price of ₹311.00. The stock has a market capitalization of 3,389 Cr. and recorded a high/low of 390/128 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹213 Cr and total liabilities of ₹248 Cr.

What is the Market Cap of Gujarat Themis Biosyn Ltd?

The Market Cap of Gujarat Themis Biosyn Ltd is 3,389 Cr..

What is the current Stock Price of Gujarat Themis Biosyn Ltd as on 23 December 2024?

The current stock price of Gujarat Themis Biosyn Ltd as on 23 December 2024 is 311.

What is the High / Low of Gujarat Themis Biosyn Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Gujarat Themis Biosyn Ltd stocks is 390/128.

What is the Stock P/E of Gujarat Themis Biosyn Ltd?

The Stock P/E of Gujarat Themis Biosyn Ltd is 64.3.

What is the Book Value of Gujarat Themis Biosyn Ltd?

The Book Value of Gujarat Themis Biosyn Ltd is 20.5.

What is the Dividend Yield of Gujarat Themis Biosyn Ltd?

The Dividend Yield of Gujarat Themis Biosyn Ltd is 0.22 %.

What is the ROCE of Gujarat Themis Biosyn Ltd?

The ROCE of Gujarat Themis Biosyn Ltd is 45.0 %.

What is the ROE of Gujarat Themis Biosyn Ltd?

The ROE of Gujarat Themis Biosyn Ltd is 33.8 %.

What is the Face Value of Gujarat Themis Biosyn Ltd?

The Face Value of Gujarat Themis Biosyn Ltd is 1.00.